儿童偏头痛预防药物治疗指南更新
多数随机对照试验未显示预防药物优于安慰剂,推荐关注生活方式与行为因素、评估共病,并与患者及照护者共同决策。
要点
- 多数预防药物随机对照试验未证实优于安慰剂,用药需共同决策。
- 普萘洛尔可能、托吡酯与桂利嗪很可能减少头痛频率。
- 推荐咨询影响头痛频率的生活方式与行为因素并管理共病。
核心结论
- 多数儿童偏头痛预防药物随机对照试验未显示优于安慰剂,推荐共同决策并讨论证据局限。
主要发现
- 接受普萘洛尔的偏头痛儿童比安慰剂组可能更易达到头痛频率至少减少50%。
- 接受托吡酯和桂利嗪的儿童青少年比安慰剂组很可能头痛频率下降。
- 接受双丙戊酸、onabotulinumtoxinA、阿米替林、尼莫地平或氟桂利嗪者与安慰剂组头痛频率减少的差异证据不足。
- 阿米替林联合认知行为疗法比阿米替林联合头痛教育更可能减少头痛频率。
关键数值与推荐
- 推荐咨询影响头痛频率的生活方式与行为因素。
- 推荐评估和管理与头痛持续相关的共病。
- 推荐临床医生与患者及照护者就偏头痛预防治疗开展共同决策,并讨论支持药物治疗的证据局限。
临床怎么用
- 对儿童偏头痛先评估共病并咨询生活方式与行为因素,再与家庭共同决定是否用药。
局限性
- 多数随机对照试验未显示预防药物优于安慰剂,药物预防证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To provide updated evidence-based recommendations for migraine prevention using pharmacologic treatment with or without cognitive behavioral therapy in the pediatric population. METHODS: The authors systematically reviewed literature from January 2003 to August 2017 and developed practice recommendations using the American Academy of Neurology 2011 process, as amended. RESULTS: Fifteen Class I-III studies on migraine prevention in children and adolescents met inclusion criteria. There is insufficient evidence to determine if children and adolescents receiving divalproex, onabotulinumtoxinA, amitriptyline, nimodipine, or flunarizine are more or less likely than those receiving placebo to have a reduction in headache frequency. Children with migraine receiving propranolol are possibly more likely than those receiving placebo to have an at least 50% reduction in headache frequency. Children and adolescents receiving topiramate and cinnarizine are probably more likely than those receiving placebo to have a decrease in headache frequency. Children with migraine receiving amitriptyline plus cognitive behavioral therapy are more likely than those receiving amitriptyline plus headache education to have a reduction in headache frequency. RECOMMENDATIONS: The majority of randomized controlled trials studying the efficacy of preventive medications for pediatric migraine fail to demonstrate superiority to placebo. Recommendations for the prevention of migraine in children include counseling on lifestyle and behavioral factors that influence headache frequency and assessment and management of comorbid disorders associated with headache persistence. Clinicians should engage in shared decision-making with patients and caregivers regarding the use of preventive treatments for migraine, including discussion of the limitations in the evidence to support pharmacologic treatments.
引用
- Oskoui M, Pringsheim T, Billinghurst L, et al. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2019. PMID: 31413170. doi:10.1212/WNL.0000000000008105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。